Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 163 Other hematologic neoplasm 52 Classical hematology 4 Myeloid 3 CNS 2 Tumor-Agnostic 1 Genitourinary 1

Conditions

Interventions

pembrolizumab 24 Specimen Handling 22 Biopsy 22 Magnetic Resonance Spectroscopy 19 Paclitaxel 11 Standard of Care 10 Bevacizumab 10 atezolizumab 9 Carboplatin 9 Nivolumab 8 Cisplatin 8 Blood Specimen Collection 8 Surveys and Questionnaires 7 Capecitabine 7 Radiosurgery 6 Pemetrexed 6 Gemcitabine 6 Cyclophosphamide 6 durvalumab 5 Taxes 5 Irinotecan 5 trastuzumab deruxtecan 4 olaparib 4 niraparib 4 cabozantinib 4 X-Rays 4 Radiotherapy 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rituximab × Tumor-Agnostic × 90 days × Clear all

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡